On‐treatment prediction of sustained response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B patients

E-ISSN： 1478-3231|35|5|1540-1548

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.5, 2015-05, pp. : 1540-1548

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG‐interferon

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 3, 2015-03 ,pp. : 318-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg‐positive chronic hepatitis B

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 473-481

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 90-96

John Wiley & Sons Inc

Access to resources Recommend Favorite

HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report

By Dong Pei-ling Zhang Xin Zhao Wen-min Ding Hui-guo

Journal of Infection and Chemotherapy, Vol. 19, Iss. 6, 2013-12 ,pp. : 1188-1192

Springer Publishing Company

Access to resources Recommend Favorite

Clinical outcomes after interruption of entecavir therapy in HBeAg‐negative chronic hepatitis B patients with compensated cirrhosis

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 10, 2015-11 ,pp. : 1182-1191

John Wiley & Sons Inc

Access to resources Recommend Favorite